ACR Boston 2014 | Daily Highlights

Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study

Abstract: 519
Presenter: Boulos Haraoui
Co-Authors: Gustavo Casado, Elke Theander, Laszlo Czirják, Andrew Taylor, Peter Button, Lykke Hinsch Gylvin and Roberto Caporali

Background:
Tocilizumab (TCZ) is indicated for the treatment of patients with RA who have had inadequate responses to DMARDs either as monotherapy (Mono) or in combination with DMARDs (Combo). ACT-UP is an umbrella project with data pooled from several international, observational, postmarketing studies investigating intravenous TCZ use in patients with RA in routine care. Interim observations of patterns of TCZ use, adherence to label recommendations, and safety are reported.

Methods:
Adult patients with moderate to severe RA who started TCZ within 8 wk of enrollment were observed in clinical practice for 6 mo. There were no specified dosing regimens (concomitant RA treatments were permitted) and no interventional procedures, clinic visits, or laboratory analyses outside routine practice.

Results:
Of 961 patients who received their first TCZ dose by June 30, 2013, 352 (37%) started Mono and 609 (63%) started Combo; 94% and 95% of Mono and Combo patients, respectively, started TCZ at 8 mg/kg, and 93% and 94% of patients, respectively, who received TCZ at 6 mo received 8 mg/kg. TCZ dose changes were reported for 34 (10%) Mono patients (7 increased, 11 decreased, 16 both increased and decreased) and 68 (11%) Combo patients (13 increased, 20 decreased, 35 both increased and decreased). Reasons for dose changes were AEs for 4% of Mono and 5% of Combo patients and lack of efficacy for 2% of Mono and 1% of Combo patients. Median MTX dose for Combo patients was 15.0 mg/wk. Sixty-three patients changed MTX dose during the study at a median dose change of –5.0 mg/wk. Twenty-eight (8%) patients who started TCZ Mono added a DMARD during the study. Corticosteroids were used by 57% of Mono and 70% of Combo patients (median prednisone-equivalent dose of 7.5 and 5.0 mg/d, respectively, at baseline). At 6 mo, 72% of Mono and 84% of Combo patients were still receiving TCZ. Overall, 100 (10%) patients discontinued TCZ in the first 3 mo and another 94 (10%) discontinued in the next 3 mo. Reasons for discontinuations included lack of efficacy (11% Mono; 27% Combo), adverse events (AEs; 27% Mono, 29% Combo), and other (62% Mono, 44% Combo). Regarding safety, AEs occurred in 53% of patients in each group. AEs classified as infections were less common in Mono than Combo patients (Table). No gastrointestinal perforations were reported in either group. Among patients for whom an AE required TCZ dose modification or an abnormal laboratory test result required follow-up, the investigator reported that local label/protocol recommendations were followed for 98% of Mono and 95% of Combo patients.

Conclusions:
In this multinational observational study, 37% of patients started TCZ as monotherapy in clinical practice. Most patients continued TCZ treatment 6 mo after initiation whether they started it as monotherapy or in combination with DMARDs. TCZ was well tolerated in both groups, and adherence to local label recommendations was high.

Disclosure of Interest:
B. Haraoui, Amgen, BMS, 2, AbbVie, Amgen, BMS, Janssen, Pfizer, Roche, UCB, 5; G. Casado, AstraZeneca, AbbVie, GSK, Janssen, Pfizer, Roche, 5; E. Theander, None; L. Czirják, AbbVie, Pfizer, Roche, UCB, MSD, 5; A. Taylor, AbbVie, Roche, Celgene, Janssen, BMS, UCB, 5, AbbVie, roche, Janssen, BMS, UCB, 8; P. Button, Roche Pharmaceuticals, 3; L. Hinsch Gylvin, Roche Pharmaceuticals, 3; R. Caporali, None.

Comment:
Es handelt sich hier um die vorläufigen Resultate einer multinationalen ‚real life' Beobachtungsstudie (ACT-UP) zum Gebrauch von Tocilizumab und seiner Sicherheit über den Zeitraum von 6 Monaten seit Therapiestart.

Insgesamt 961 begannen mit der Therapie, davon 37% als Mono- und entsprechend 63% als Kombinationstherapie, in aller Regel mit 8 mg/kg. Bei 10 bzw. 11% wurden innerhalb von 6 Monaten Dosisanpassungen nach oben oder unten angenommen. 57 bzw. 70 erhielten gleichzeitig Cortison mit einem Prednison-Äquivalent von 7.5 bzw. 5 mg/d.

Nach 6 Monaten waren 72 bzw. 84% noch auf Mono- oder Kombinationstherapie mit Tocilizumab.

Adverse events waren bei 53% der Patienten beider Gruppen zu verzeichnen. Bezgl. severe adverse events gab es ebenfalls keinen wesentlichen Unterschied und sie lagen im erwarteten niedrigen Bereich.

Man kann ingesamt aus diesen Daten sehen, dass in der täglichen Praxis Tocilizumab nicht selten als Monotherapie angewendet wurde, dass die Adhärenz zur Medikation über einen Zeitraum von 6 Monaten recht hoch war und die Medikation gut vertragen wurde ohne unerwartet hohe oder neue Sicherheitssignale.

---

> zurück zur Übersicht